Key Highlights

  • Algorae Pharmaceuticals combines AI-enabled drug discovery with pharmaceutical commercialisation.
  • Peter Mac testing validated AlgoraeOS v2 in July 2026.
  • The company also announced an NSW Health public hospital Supply contract in July.
  • 1AI shares rose 5.00% to AUD 0.011 at the time of writing on 1 September 2026.

Algorae Pharmaceuticals (ASX: 1AI) shares rose 5.00% to AUD 0.011 at the time of writing on 1 September 2026. Algorae Pharmaceuticals Limited (ASX: 1AI) continues to operate across two connected areas: AI-enabled drug discovery and pharmaceutical commercialisation. Its 2026 announcements have covered the development of AlgoraeOS, supply contracts and the expansion of its commercial platform. The company’s latest reporting keeps these two activities together within its broader corporate strategy.

AlgoraeOS Moves Through Validation

On 3 July 2026, the company announced that testing at Peter Mac had validated AlgoraeOS v2. The announcement marked another disclosed step in the development of the company’s AI drug-discovery platform, which sits alongside its commercial pharmaceutical operations. AlgoraeOS therefore remains one of the technology-focused strands in the company’s development program.

Commercial Activity Adds Another Workstream

Algorae also announced an NSW Health public hospital supply contract in July. Earlier in the year, the company entered an exclusive commercial agreement with Zydus. These disclosures show the company pursuing pharmaceutical supply opportunities while continuing to develop its AI platform. The combination gives the company two distinct areas of disclosed activity: commercial pharmaceutical supply and AI-enabled drug discovery.

1AI Share Price Snapshot

At the time of writing on 1 September 2026, 1AI shares rose 5.00% to AUD 0.011. The latest company story remains the combination of AI development and pharmaceutical commercialisation. Future company disclosures will provide the next milestones for both areas.